Biocartis Group NV announced the signing of a new companion diagnostic development agreement with Amgen aimed at the development of Idylla(TM) CDx biomarker tests for a novel oncology compound to be used in the treatment of certain solid tumors. This is the second CDx agreement that Biocartis has signed with Amgen. The first CDx agreement between both companies was announced on December 4, 2017 and aims to register the Idylla(TM) KRAS Mutation Test and the Idylla(TM) NRAS-BRAF Mutation Test with the US Food and Drug Administration (FDA) as a CDx test for Amgen's drug Vectibix.